Considering the totality of evidence from clinical trials, post-marketing reports and observational studies, alongside the generally low incidence rate of NAION, Novo Nordisk believes that the benefit-risk profile of semaglutide remains favorable, the spokesperson said.
Despite nine AOMs being currently approved for the treatment of obesity, limited clinical trial evidence in older adults predominantly focuses on incretin therapy with glucagon-like peptide-1 receptor agonists (liraglutide, semaglutide, and tirzepatide)
It is commonly employed in in vitro fat-cell studies and preclinical metabolic investigations
747-257-0777 Book Online www.vidaskinbeautycenter.com
Caution is advised, particularly if you are on medications with a narrow therapeutic index (i.e., drugs that require precise dosing)
[PMID: 8681902] PubMed record related to this compound for laboratory literature review